https://www.selleckchem.com/
Selective GluN2B/N-methyl-D-aspartate receptor (NMDAR) antagonists have exposed their clinical effectiveness in cluster of neurodegenerative diseases such as Epilepsy, Alzheimer's disease, Parkinson's disease, pain and depression. Hence, GluN2B/NMDAR is considered to be a prospective target for the management of neurodegenerative diseases. Here, we have discussed current results and significance of subunit selective GluN2B/NMDAR antagonists to pave the way for establishment of new, safe, and economical drug candidate in a near future. Using summarized data
Like
Comment
Share
